Abstracts tagged "ANCA"

Abstract Number: 749 • 2013 ACR/ARHP Annual Meeting
High Clinical Remission Rate With Relatively High Incidence Of Serious Infection In Newly-Onset ANCA-Associated Vasculitides In Japan – A Report From The Nationwide Prospective Cohort Study
Masayoshi Harigai¹, Ken-ei Sada², Takao Fujii³, Masahiro Yamamura⁴, Yoshihiro Arimura⁵ and Hirofumi Makino², ¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ²Department of Medicine and Clinical Science, Okayama University, Okayama, Japan, ³Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Center for Rheumatology, Okayama Saiseikai Hospital, Okayama, Japan, ⁵First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Clinical characteristics and antineutrophil cytoplasmic antibody (ANCA)-serology of ANCA-associated vasculitis (AAV) patients are substantially different between Western and Asian countries. We investigated effectiveness and…
Abstract Number: 750 • 2013 ACR/ARHP Annual Meeting
Maintenance Treatment In Childhood Granulomatosis With Polyangiitis
Marinka Twilt¹, Rayfel Schneider², Diane Hebert³, Elizabeth Harvey³, Ronald M. Laxer², Sharon Dell⁴, Christoph Licht³ and Susanne M. Benseler², ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Nephrology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is a rare but life threatening disease. Most children present with pulmonary bleeds and/or renal failure. Most treatment regimens are…
Abstract Number: 753 • 2013 ACR/ARHP Annual Meeting
Validation Of The New Histopathological Classification Of ANCA Glomerulonephritis and Its Association With Renal Outcomes In a Paediatric Population
Marinka Twilt¹, Damien Noone², Wesley Hayes², Paul Thorner³, Susanne M. Benseler⁴, Ronald M. Laxer⁴, Rulan Parekh² and Diane Hebert², ¹Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Nephrology, The Hospital for Sick Children, Toronto, ON, Canada, ³Pathology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated glomerulonephritides (ANCA GN) include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Churg-Strauss. A novel histopathologic classification for GPA…
Abstract Number: 754 • 2013 ACR/ARHP Annual Meeting
Outcome Of Kidney Transplantation In Paediatric Patients With ANCA Associated Glomerulonephritis: A Single-Center Experience
Marinka Twilt¹, Damien Noone², Wesley Hayes², Paul Thorner³, Susanne M. Benseler⁴, Ronald M. Laxer⁴, Rulan Parekh² and Diane Hebert², ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Nephrology, The Hospital for Sick Children, Toronto, ON, Canada, ³Pathology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Kidney transplant outcomes for paediatric patients with end stage kidney disease (ESKD) secondary to ANCA GN, particularly granulomatosis with polyangiitis (GPA) and microscopic polyangiitis…
Abstract Number: 755 • 2013 ACR/ARHP Annual Meeting
Survival Of Patients With ANCA-Associated Vasculitides In Chronic Dialysis In France From 2002 To 2011: Data From The National Rein Registry
Manon Romeu¹, Cécile Couchoud Sr.², Jean-Christophe Delarozière³, Laurent Chiche Sr.⁴, Jean-Robert Harle⁵, Bertrand Gondoin⁶, Stéphane Burtey⁶, Philippe Brunet⁶, Yvon Berland⁶ and Noémie Jourde-Chiche Sr.⁷, ¹Nephrology, Aix-Marseille Universite, APHM, Marseille, France, ²registre REIN, agence de la biomédecine, paris, France, ³public health, APHM, Marseille, France, ⁴Internal Medicine, CHU Marseille, Marseille, France, ⁵Internal Medicine, APHM, Marseille, France, ⁶Nephrology, APHM, Marseille, France, ⁷Nephrology, Aix-Marseille Université - APHM, Marseille, France
Background/Purpose: Despite dramatic outcome improvement in ANCA-associated vasculitides (AAV), renal involvement is still leading to end-stage renal disease (ESRD) in 20-30% of patients. This study…
Abstract Number: 760 • 2013 ACR/ARHP Annual Meeting
Cluster Analysis To Explore Clinical Subclassification Of Eosinophilic Granulomatosis With Polyangiitis (Churg–Strauss)
Thomas Neumann¹, Frank Moosig², Augusto Vaglio³, Jochen Zwerina⁴, Renato Alberto Sinico⁵, Wojciech Szczeklik⁶, Paolo Bottero⁷, Phillip Bremer⁸, Andrea Gioffredi⁹, Barbara Sokolowska⁶, Luca Di Toma⁵, Federica Maritati⁹, Julian Großkreutz¹⁰, Claus Kroegel¹¹, Matthieu Resche-Rigon¹² and Alfred Mahr¹³, ¹Jena University Hospital, Internal Medicine III, Jena, Germany, ²Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ³Unit of Nephrology, University Hospital of Parma, Parma, Italy, ⁴Ludwig Bolzmann institut of osteology at the 4th medical departmen, Hanusch Hospital, Vienna, Austria, ⁵Clinical Immunology Unit and Renal Unit, Department of Medicine, Azienda Ospedaliera Ospedale San Carlo Borromeo, Milan, Italy, ⁶Department of Medicine, Jagiellonian University Medical College, Krakow, Poland, ⁷llergy and Clinical Immunology Unit, Magenta Hospital, Magenta, Italy, ⁸University Hospital Schleswig Holstein and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, ⁹Department of Clinical Medicine, Nephrology and Health Sciences, University of Parma, Parma, Italy, ¹⁰Department of Neurology, Jena University-Hospital, Jena, Germany, ¹¹Jena University Hospital, Internal Medicine I, Jena, Germany, ¹²Biostatistics, Hopital Saint-Louis, Paris, France, ¹³Department of Internal Medicine, Hospital Saint-Louis, Paris, France
Background/Purpose: Results from descriptive studies of eosinophilic granulomatosis with polyangiitis (EGPA) suggest distinct clinical subclasses that may be determined by anti-neutrophil cytoplasmic antibody (ANCA) status.…
Abstract Number: 729 • 2013 ACR/ARHP Annual Meeting
Role Of Innate Immunity In The Pathogenesis Of ANCA-Associated Vasculitis
Angelica Gattamelata¹, Giovanna Peruzzi², Rossana Scrivo³, Roberta Priori³, Stefania Morrone⁴, Angela Santoni² and Guido Valesini³, ¹Sapienza University of Rome, Rome, Italy, ²Department of Molecular Medicine, Sapienza University, Rome, Italy, ³Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁴Department of Experimental Medicine, Sapienza University, Rome, Italy
Background/Purpose: Natural killer cells (NK) represent one of the main effectors of the innate immune response through the defense against viral infections and the production…
Abstract Number: 2564 • 2012 ACR/ARHP Annual Meeting
A Risk Score for Predicting Short-Term Incidence of Death or Relapse in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Carla Maldini¹, Matthieu Resche-Rigon², David Jayne³, Kerstin Westman⁴ and Alfred Mahr¹, ¹Internal Medicine, Hospital Saint-Louis, Paris, France, ²Biostatistics, Hopital Saint-Louis, Paris, France, ³Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁴Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), combining granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), is associated with a substantial risk of relapse or…
Abstract Number: 1535 • 2012 ACR/ARHP Annual Meeting
Genetic Background of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Japanese Population: Association of STAT4 with Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Positive Vasculitis
Aya Kawasaki¹, Naoya Inoue¹, Chihiro Ajimi¹, Ikue Ito¹, Ken-ei Sada², Shigeto Kobayashi³, Hidehiro Yamada⁴, Hiroshi Furukawa⁵, Makoto Tomita⁶, Takayuki Sumida⁷, Shigeto Tohma⁸, Nobuyuki Miyasaka⁹, Shoichi Ozaki⁴, Hiroshi Hashimoto¹⁰, Hiroshi Makino², Masayoshi Harigai¹¹ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Medicine and Clinical Science, Okayama University, Okayama, Japan, ³Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University, Kawasaki, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁶Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ⁷Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁸Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan, ⁹Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁰Juntendo University School of Medicine, Tokyo, Japan, ¹¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: In antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), geographic difference in the type of vasculitis is well known. While granulomatosis with polyangiitis (GPA) is the…
Abstract Number: 2565 • 2012 ACR/ARHP Annual Meeting
Prevalence of Anti-Neutrophil Cytoplasmic Antibodies in Infective Endocarditis: An Analysis of 109 Cases
Alfred Mahr¹, Frédéric Batteux², Sarah Tubiana³, Michel Wolff⁴, Claire Goulvestre², Thomas Papo⁵, François Vrtovsnik⁶, Isabelle Klein⁷, Bernard Iung⁸ and Xavier Duval⁹, ¹Internal Medicine, Hospital Saint-Louis, Paris, France, ²Laboratoire d'Immunologie, Hospital Cochin, Paris, France, ³Clinical Investigation, Hospital Bichat, Paris, France, ⁴Intensive Care Unit, Hospital Bichat, Paris, France, ⁵Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ⁶Nephrology, Hospital Bichat, Paris, France, ⁷Radiology, University Paris-7, APHP, Bichat Hospital, Paris, France, ⁸Cardiology, Hospital Bichat, Paris, France, ⁹Infectious Diseases, Hospital Bichat, Paris, France
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCAs), particularly those directed against proteinase 3 (anti-PR3) or myeloperoxydase (anti-MPO), are considered a highly specific hallmark of ANCA-associated vasculitis. Thus,…
Abstract Number: 1536 • 2012 ACR/ARHP Annual Meeting
Clinical Features of Patients with Anti-Neutrophil Cytoplasmic Autoantibodies Targeting Native Myeloperoxidase Antigen
Yuji Yamanishi¹, Toshiko Ito-Ihara², Shigeto Kobayashi³, Peter Y. Shane⁴, Gary S. Firestein⁵, Hiroshi Hashimoto⁶ and Kazuo Suzuki⁷, ¹Division of Rheumatology, Hiroshima Rheumatology Clinic, Hiroshima, Japan, ²Department of Clinical Innovative Medicine, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, ³Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Div of Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁶Juntendo Tokyo Koto Geriatric Center, Tokyo, Japan, ⁷National Institute of Infectious Diseases, Tokyo, Japan
Background/Purpose: ANCA is a useful diagnostic marker in systemic vasculitic disorders with small-vessel involvement, but depending on the particular test used the myeloperoxidase (MPO)-ANCA results…
Abstract Number: 2393 • 2012 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Levels Are Not Associated with Subclinical Carotid Atherosclerosis in Patients with Granulomatosis with Polyangiitis but Are Reduced by Glucocorticoids and Statins
Alexandre Wagner S. de Souza¹, Karina de Leeuw², Johanna Westra², Andries J. Smit³, Anne Marijn van der Graaf², Hans L. A. Nienhuis¹, Johan Bijzet², Pieter C. Limburg⁴, Coen A. Stegeman⁵, Marc Bijl⁶ and Cees G.M. Kallenberg², ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Vascular Diseases, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Department of Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁵Nephrology, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, Martini Hospital, Groningen, Netherlands
Background/Purpose: High mobility group box 1 (HMGB1) is a non-histone DNA binding protein that is passively released by dying cells or actively secreted by immunocompetent…
Abstract Number: 860 • 2012 ACR/ARHP Annual Meeting
Interleukin-21, B Cell Activating Factor and Unmethylated CpG Oligodeoxynucleotides Synergize in Promoting Anti-Proteinase 3 Autoantibody Production in Vitro
Nikola Lepse¹, Judith Land², Abraham Rutgers², Cees G.M. Kallenberg², Coen A. Stegeman³, Peter Heeringa¹ and Wayel H. Abdulahad², ¹Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Nephrology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are characterized by the presence of circulating autoantibodies that are often directed against proteinase 3 (PR3). Although the…
Abstract Number: 2379 • 2012 ACR/ARHP Annual Meeting
Successful Treatment of Churg-Strauss Syndrome with Rituximab
Christin Dubrau¹, Fabian Arndt², Wolfgang L. Gross and Frank Moosig⁴, ¹Departement of Rheumatology and Clinical Immunology, University Hospital Schleswig-Holstein, Campus Luebeck and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, ²Departement of rheumatology and clinical immunology, University Hospital Schleswig Holstein and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, ³Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany
Background/Purpose: Rituximab has recently been shown to be equipotent to cyclophosphamide for induction of remission in generalized ANCA-associated vasculitis. A substantial number of observational pro-…
Abstract Number: 2383 • 2012 ACR/ARHP Annual Meeting
Rituximab As Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients
Pierre Charles¹, Antoine Néel², Nathalie Tieulié³, Arnaud Hot⁴, Grégory Pugnet⁵, Olivier Decaux⁶, Isabelle Marie⁷, Mehdi Khellaf⁸, Jean-Emmanuel Kahn⁹, Alexandre Karras¹⁰, Jean-Marc Ziza¹¹, Christophe Deligny¹², Colas Tchérakian¹³ and Loic Guillevin¹⁴, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²Internal Medicine, Nantes University Hospital, Nantes, France, ³CHU Nice, Nice, France, ⁴Internal Medicine, Edouard Herriot University Hospital, Lyon, France, ⁵Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ⁶Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁷Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, ⁸Internal Medicine, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ⁹Internal Medicine, Foch Hospital, Suresnes, France, ¹⁰Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ¹¹Rheumatology, Croix Saint Simon Hospital, Paris, France, ¹²Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ¹³Service de pneumologie, hôpital Foch, Suresnes, France, ¹⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Rituximab has been shown to induce remission of ANCA-associated vasculitis (AAV). Our study was undertaken to 1) describe the clinical response of AAV to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].